HTX 0.00% 0.1¢ healthlinx limited

Page 1 of 1MARKET RELEASE3 August 2012HealthLinx LimitedTRADING...

  1. 872 Posts.
    Page 1 of 1
    MARKET RELEASE
    3 August 2012
    HealthLinx Limited
    TRADING HALT
    The securities of HealthLinx Limited (the “Company”) will be placed in Trading Halt
    Session State at the request of the Company, pending the release of an announcement
    by the Company. Unless ASX decides otherwise, the securities will remain in Trading
    Halt Session State until the earlier of the commencement of normal trading on Tuesday,
    7 August 2012 or when the announcement is released to the market.
    Security Code: HTX
    Kobe Li
    Senior Adviser, Listings (Melbourne)
    HealthLinx Limited
    ABN 88 098 640 352
    576 Swan Street Richmond VIC 3121
    Telephone: +61 3 9208 4200 I Facsimile: +61 3 9208 4201
    www.healthlinx.com.au
    3 August 2012
    ASX Market Announcements
    Australian Securities Exchange Limited
    Level 4, Rialto,
    525 Collins Street,
    Melbourne VIC 3000
    REQUEST FOR TRADING HALT
    In accordance with Listing Rule 17.2 the Company requests a trading halt pending a material
    price sensitive announcement. The reasons are:
    • The Company expects to make a material price sensitive announcement within the next 24 hours
    regarding a substantial asset sale;
    • The Company is concerned about confidentiality because outside parties have been involved in
    various ways;
    • The Company requests that trading be halted at market open today until immediately after the
    expected announcement is made or until 10:00am on Monday August 6, whichever is the earlier;
    • The Company is not aware of any reason why its securities should not be temporarily suspended.
    Mal Lucas-Smith
    Company Secretary
    About HealthLinx Limited (ASX:HTX)
    HealthLinx uses biomarkers to develop best practice diagnostics that detect and monitor diseases.
    First commercial targets are for diseases with high fatality:
    • Ovarian cancer diagnostic (OvPlex) targeting US$270m pa market
    • Prostate cancer targeting US$350m pa market
    A biomarker is a specific biochemical in the body that measures disease or the effects of treatment.
    HealthLinx is close to completing the second larger study for OvPlexTM aiming to prove the diagnostic
    accuracy for ovarian cancer. This larger study is based on approximately 1150 new samples using
    existing OvPlex™ biomarkers. The study will be a robust comparison of sensitivity and specificity
    especially for early stage diagnosis in symptomatic women. The objective is to cement the position of
    OvPlex™ as the world’s most accurate and efficient ovarian cancer diagnostic. The second study is
    partially funded with $750,000 from the Victorian Government Victoria’s Science Agenda Investment
 
watchlist Created with Sketch. Add HTX (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.